On May 15, 2020, ADC Therapeutics listed its shares on the New York Stock Exchange (ticker symbol ADCT). ADCT is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of antibody drug conjugates. Through its IPO, at Usd 19 per share, ADCT raises gross proceeds of USD 267 m including greenshoe. At market close on the first day of trading, ADCT had a market capitalization of USD 2.1 bn. ADCT is the first Swiss company to go public in 2020.
Homburger advises ADC Therapeutics. The team is led by partner Dieter Gericke (corporate and m&a – pictured) and includes partners Reto Heuberger and Stefan Oesterhelt (both tax), Benjamin Leisinger (banking and finance), as well as associates Daniel Häusermann, Estelle Piccard (both corporate and m&a), Olivier Baum (banking and finance), Manuel Dubach (tax) and junior associate Oliver Kneubühl (corporate and m&a).